ArticleBMC women's health2025
The role of micro-, meso-, and macro-level stigma on the uptake of medications for opioid use disorder (MOUD) among women in the criminal legal system.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reducing Buprenorphine Misinformation as a Strategy to Improve Adoption in Primary Care.Substance use & misuse · 2026Article
- Housing instability and economic insecurity across the continuum of active substance use, treatment, and recovery among women involved in the criminal legal system.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWomen with a history of opioid use disorder (OUD) and criminal legal involvement face rising overdose rates and barriers to engagement in medications for opioid use disorder (MOUD) treatment. Intensified by gender and criminal legal status, experiences of stigma can negatively influence MOUD treatment outcomes among women. While the effectiveness of MOUD in treating OUD is well-documented, there is a gap in understanding how MOUD-related stigma impacts engagement in MOUD treatment, particularly among criminal-legal involved women. To address this gap, we applied the FINIS model (Framework Integrating Normative Influences on Stigma) to explore how MOUD-related stigma manifests for criminal legal-involved women at the micro (intrapersonal), meso (interpersonal/institutional), and macro (structural/policy) levels.
methodsFrom May to July 2022, semi-structured qualitative interviews (N = 42) were conducted in Pennsylvania. Participants included women with a lifetime history of MOUD use and criminal legal system involvement (N = 20), criminal legal professionals (N = 10), and SUD treatment professionals (N = 12) who work with women who use opioids. The interviews explored participants’ lived or working experience with substance use, MOUD treatment, criminal legal involvement, and gender-specific issues around such. Data were analyzed utilizing thematic analysis.
resultsUtilizing the FINIS model, our thematic analysis identified influences to MOUD uptake across the three levels of stigma: (1) micro-level (internalized beliefs), (2) meso-level (stigma encountered across settings) and (3) macro-level (structural and institutional barriers). A recurring theme across levels was the existence of a MOUD hierarchy—specifically, stigma surrounding methadone as a treatment for OUD.
conclusionThis study’s findings show how MOUD-related stigma operates simultaneously at the three levels, undermining treatment and recovery for criminal-legal involved women. Interpretation of these results through the FINIS model further highlights that stigma is not only experienced internally but also reinforced through peer dynamics, provider attitudes, and policies within criminal legal settings. Ultimately, reducing stigma across all levels will require systemic reforms, targeted education programs for providers, and recovery models that validate diverse treatment pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.